{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-110174","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2025-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.183993+00:00","generated_at":"2026-05-17T11:31:16.232938+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"HCW Biologics receives Nasdaq delisting notice over equity non-compliance","bullets":["Received notice Aug 19, 2025 that as of June 30, 2025 it is non-compliant with Nasdaq Equity Rule 5550(b)(1).","Trading suspension set for Aug 28, 2025 unless hearing requested by Aug 26; company plans to request stay.","Subject to Panel Monitor through June 23, 2026; no compliance plan opportunity if non-compliant again.","Company considering all options but no assurance the Panel will grant continued listing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-110174","json":"https://secwatch.observer/filing/0000950170-25-110174.json","markdown":"https://secwatch.observer/filing/0000950170-25-110174.md","text":"https://secwatch.observer/filing/0000950170-25-110174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025110174/0000950170-25-110174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025110174/hcwb-20250819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:31:16.232938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ba063a4735281b3081e7596d841d1f781925312","claim":"HCW Biologics Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"June 26, 2025, HCW Biologics Inc. (the “Company”) announced that it received formal notice from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that the Company was in compliance with Listing Rule 5550(b)(1) (the “Equity Rule”) for continued listing of its securities on the Nasdaq Capital Market tier. The Company was also notified that it will remain subject to a “Panel Monitor,” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through June 23, 2026. If, during the term of the Pan","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025110174/0000950170-25-110174-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"f863771edb1437e01f26b635f16a239eb8a404c9","claim":"HCW Biologics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"August 19, 2025, the Company received written notice from the Staff that as of June 30, 2025, the Company was non-compliant with the Equity Rule, so its securities would be suspended from trading on Nasdaq on August 28, 2025 unless it requests a hearing by August 26, 2025. The Company plans to timely request a hearing before the Panel, which will stay the suspension of trading of the Company's securities on Nasdaq pending completion of the hearing process. The Company is considering all options available to it to regain compliance with the Equity Rule; however, there can be no assurance that t","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025110174/0000950170-25-110174-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}